Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 2,349 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 SARS-CoV-2 Infection Clear all
Recruiting Phase 3 Interventional

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

NCT05261139
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
50
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients

NCT04364802
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Povidone-Iodine Nasal Spray and Gargle
Drug
Lead sponsor
Nikita Gupta
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 15, 2026, 10:29 PM EDT
Recruiting Not applicable Interventional

Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19

NCT04858412
View directory record Official record
Conditions
Alcoholic Liver Disease, COVID 19 Pneumonia
Interventions
β-hydroxy β-methyl butyrate (HMB) enriched amino acid, Balanced amino acid
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis

NCT04331795
View directory record Official record
Conditions
COVID-19
Interventions
Tocilizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 15, 2026, 10:29 PM EDT
Completed No phase listed Observational

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

NCT04884477
View directory record Official record
Conditions
COVID-19, Immunosuppressed Host, Convalescent Plasma, Anti-CD20 Therapy
Interventions
Convalescent Plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 15, 2026, 10:29 PM EDT
Completed No phase listed Observational

Needs of Persons with Spinal Cord Injury (SCI)

NCT04422769
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

NCT04958954
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 15, 2026, 10:29 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray

NCT05437029
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Q-Griffithsin 3.0, Q-Griffithsin 6.0
Drug
Lead sponsor
Kenneth Palmer
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress

NCT04800120
View directory record Official record
Conditions
Covid19
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Taunton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 15, 2026, 10:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prophylaxis and Treatment of COVID-19

NCT04844541
View directory record Official record
Conditions
COVID-19, Acute Respiratory Infection
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 15, 2026, 10:29 PM EDT
Enrolling by invitation Not applicable Interventional

A Spatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs

NCT05769023
View directory record Official record
Conditions
COVID-19
Interventions
Intervention test
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

University of Utah COVID-19 Hydrochloroquine Trial

NCT04342169
View directory record Official record
Conditions
Coronavirus Infection, Coronavirus, Infectious Disease
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 15, 2026, 10:29 PM EDT
Withdrawn Phase 2 Interventional

COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

NCT05040776
View directory record Official record
Conditions
Thrombopenia, Covid19
Interventions
EP-7041 Injection
Drug
Lead sponsor
eXIthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

Multi-site Adaptive Trials for COVID-19

NCT04370262
View directory record Official record
Conditions
COVID-19
Interventions
SOC + Intravenous Famotidine, SOC + Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Baby2Home (B2H) Mobile Health Application

NCT05595486
View directory record Official record
Conditions
COVID-19 Pandemic, Health Knowledge, Attitudes, Practice, Perinatal Depression, Mental Health Wellness, Post Partum Depression
Interventions
Baby2Home Mobile Application
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 15, 2026, 10:29 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Working Towards Empowered Community-driven Approaches to Increase Vaccination and Preventive Care Engagement

NCT05841810
View directory record Official record
Conditions
COVID-19
Interventions
mHealth Outreach, Care Coordination
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
4
States / cities
El Cajon, California • Escondido, California • La Jolla, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 15, 2026, 10:29 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

NCT04323761
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Remdesivir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 15, 2026, 10:29 PM EDT
Terminated Phase 2 Interventional Results available

Treating COVID-19 With Hydroxychloroquine (TEACH)

NCT04369742
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ), Placebo: Calcium citrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 15, 2026, 10:29 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Engaging Staff to Improve COVID-19 Vaccination Response at Long-Term Care Facilities

NCT05449418
View directory record Official record
Conditions
COVID-19
Interventions
Full Intervention, Enhanced Usual Care
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Planning Message Recommending Same Time/Location as Last Vaccine

NCT05612386
View directory record Official record
Conditions
COVID-19
Interventions
COVID Booster text messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
520,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 15, 2026, 10:29 PM EDT